Treatment

ASPAVELI 1 080 mg solution for infusion clinical trials

2 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
This study is testing a new medicine, Pegcetacoplan, for kidney diseases called C3 Glomerulopathy and IC-MPGN. It wants to see if the medicine can help reduce protein in the urine and improve kidney health, compared to a dummy treatment.
For: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
Austria · Netherlands · Italy
Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC‑MPGN
This study looks at a new medicine called Pegcetacoplan for people who have kidney problems like C3G or IC-MPGN after a kidney transplant. Researchers want to see if the medicine can reduce harmful deposits in the kidney and if it's safe to use.
For: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
Netherlands · Austria · Italy